ClinicalTrials.gg
RecruitingNCT07052396ANEMOUpdated Dec 22, 2025

Study to Evaluate Long-term Effectiveness and Safety, Patient Characteristics and Subjective Patient-reported Outcomes of Dupilumab in Patients With Chronic Obstructive Pulmonary Disease (COPD) Under Real-world Conditions

An observational study in Chronic Obstructive Pulmonary Disease (COPD), sponsored by Sanofi. Recruiting at 18 sites in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-22.

Sponsored by Sanofi · Observational

How we know · 3 judgments

From the registry’s dates

  • Started Jul 2025; still recruiting 1 year 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
350
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 15 studies in Pulmonary Disease, Chronic Obstructive by Sanofi — 7 open to participants now, 7 under way, 3 of them phase 3. Pulmonary Disease, Chronic Obstructive · Sanofi.

Started
2025
with 3 others
Observational
3 of 15
3 open now
Registered
9th of 15
by date

Among the 15 studies in Pulmonary Disease, Chronic Obstructive by Sanofi, this one is one of 4 that started in 2025, is one of 3 observational ones, and was the 9th registered.

Pulmonary Disease, Chronic Obstructive

5,529 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

7 of the 15 studies in Pulmonary Disease, Chronic Obstructive by Sanofi are open now, in 12 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Who these studies take

Of the 560 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 30 take children under 18; 88 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Pulmonary Disease, Chronic Obstructive by Sanofi, or all of them as a file.
02

Study summary

Study to evaluate the change of health-related quality of life, patient characteristics, efficacy and safety in Chronic Obstructive Pulmonary Disease (COPD) patients with Dupilumab therapy in a real-world setting over 24 months.

Read the detailed description

Non-interventional Study. Patients receive Dupilumab in accordance with the summary of product characteristics in a real-world setting. The Dupilumab initiation must be independent of the study recruitment and patient data is documented based on clinical routine.

03

Conditions studied

  • Chronic Obstructive Pulmonary Disease (COPD)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Participants will be screened, enrolled, and documented by their treating physician. To avoid any selection bias, all eligible participants will be invited to participate in this study in the order in which their eligibility is determined (consecutive recruitment). Participants will be treated within clinical routine practice and according to the current standard of care. Participants who permanently discontinue dupilumab treatment and therefore terminate the study prior to the last visit at month 24 will be requested to complete an Early Termination visit.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants willing and able to sign for use of their pseudonymized clinical data within the present non-intervention study.
  • Adult participants.
  • Participants with uncontrolled (COPD) despite long-acting muscarinic antagonist (LAMA)/ long-acting beta2-agonist (LABA)/ Inhaled (ICS) (or LAMA/LABA if ICS are not appropriate) therapy and elevated blood eosinophils
  • Participants newly initiated on dupilumab treatment as indicated in the dupilumab Summary of Product Characteristics (SmPC) in the specified label for COPD, determined by the treating physician, and independent of participation in the non-interventional study (NIS).

Exclusion criteria

Exclusion Criteria:

  • Participants not eligible for dupilumab treatment according to SmPC.
  • Participation in an ongoing interventional or observational study or participation in an interventional or observational study up to 12 months before enrolment that might, in the treating physician's opinion, influence the assessments for the current study.
  • Any acute or chronic condition that, in the treating physician´s opinion, would limit the participants´s ability to complete questionnaires or to participate in this study or impact the interpretation of the results.
  • Participants hospitalized due to an exacerbation of their within the last 4 weeks prior to enrolment.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
350 participants (estimated)
Patient registry
No

Interventions

  • This study will not administer any treatment, only observe the treatment as prescribed in real world clinical practice.

06

What researchers measure

Primary outcomes

  1. Change from Baseline in COPD Assessment Test (CAT) Score

    The COPD Assessment Test (CAT) is a questionnaire to assess the health status and quality of life of people with COPD. The questionnaire consists of eight simple statements, which participants answer using a numerical scale. The CAT score ranges from 0 to 40, with lower scores indicating a better health status.

    Time frame: Baseline up to 12 months

Secondary outcomes

  1. Change from Baseline in CAT Score

    The COPD Assessment Test (CAT) is a questionnaire to assess the health status and quality of life of people with COPD. The questionnaire consists of eight simple statements, which participants answer using a numerical scale. The CAT score ranges from 0 to 40, with lower scores indicating a better health status.

    Time frame: Baseline to up to 6 months and 24 months

  2. Analysis of Socio-demographics, Medical Disease and Treatment History

    Demographic data (age, sex \[f/m\], ethnicity, height, weight, BMI, vaccination status, smoking status, pack years) will be collected.

    Time frame: Baseline

  3. Analysis of Clinical Disease Characteristics including Exacerbations

    Number and severity grade of exacerbations in the year before study start will be assessed.

    Time frame: Baseline

  4. Analysis of Clinical Disease Characteristics including Lung Function Parameters

    Lung function parameters such as forced expiratory volume in 1 second (FEV1), forced vital capacity (FVC), FEV1/FVC, total lung capacity (TLC), residual volume (RV), sRtot, Diffusing capacity of the lungs for carbon monoxide (DLCO), DLCO/VA, Rtot, oxygen saturation in the blood will be assessed.

    Time frame: Baseline

  5. Analysis of Clinical Disease Characteristics including Eosinophils [EOS] Levels

    Analysis of clinical disease characteristics including EOS levels.

    Time frame: Baseline

  6. Analysis of Clinical Disease Characteristics including Fractional Exhaled Nitric Oxide [FeNO] Levels

    Analysis of clinical disease characteristics including FeNO levels.

    Time frame: Baseline

  7. Analysis of Clinical Disease Characteristics including Immunoglobulin E [IgE] Levels

    Analysis of clinical disease characteristics including IgE levels.

    Time frame: Baseline

  8. Analysis of Clinical Disease Characteristics including Current Global Initiative for Chronic Obstructive Lung Disease (GOLD) Grade and Group

    Analysis of clinical disease characteristics including current GOLD grade and group.

    Time frame: Baseline

  9. Analysis of Clinical Disease Characteristics including Smoking Status and Pack Years

    Analysis of clinical disease characteristics including smoking status and pack years.

    Time frame: Baseline

  10. Analysis of Clinical Disease Characteristics including Comorbidities

    Current and previous comorbidities (such as chronic rhinosinusitis, asthma, allergies, or cardiovascular comorbidities) will be assessed.

    Time frame: Baseline

  11. Analysis of Clinical Disease Characteristics including Date of COPD Diagnosis and GOLD Grade/Group at COPD Diagnosis

    Analysis of clinical disease characteristics including date of COPD diagnosis and GOLD grade/group at COPD diagnosis.

    Time frame: Baseline

  12. Annualized Rate of Moderate and Severe COPD Exacerbations

    Annualized rate of moderate and severe COPD exacerbations after 12 and 24 months versus the year before baseline.

    Time frame: Baseline to up to 12 and 24 months

  13. Change in Rate of Moderate and Severe Exacerbations

    Change in rate of moderate and severe exacerbations will be assessed.

    Time frame: Baseline to up to 6, 12 and 24 months

  14. Time to First Moderate or Severe Exacerbation Since Study Start

    Time to first moderate or severe exacerbation since study start.

    Time frame: Baseline to up to 6, 12 and 24 months

  15. Cumulative Moderate and Severe Exacerbations Over Time

    Cumulative moderate and severe exacerbations over time

    Time frame: Baseline to up to 6, 12 and 24 months

  16. Change Over Time in Pre- and Post-Bronchodilator Forced Expiratory Volume in 1 Second (FEV1)

    Change over time in pre- and post-bronchodilator FEV1 from study start.

    Time frame: Baseline to up to 6, 12 and 24 months

  17. Change Over Time in Bronchodilator FEV1/Forced Vital Capacity (FVC)

    Change over time in pre- and post- bronchodilator FEV1/FVC from study start.

    Time frame: Baseline to up to 6, 12 and 24 months

  18. Change Over Time in Modified Medical Research Council (mMRC)

    Change over time in mMRC from study start.

    Time frame: Baseline to up to 6, 12 and 24 months

  19. Number of Missed Workdays due to COPD

    Number of missed workdays due to COPD during the last year before baseline and after dupilumab treatment.

    Time frame: Baseline to up to 6, 12 and 24 months

  20. Number of Hospitalization After Dupilumab Treatment

    Number of hospitalizations after dupilumab treatment versus the year before study start.

    Time frame: Baseline to up to 6, 12 and 24 months

  21. Reason(s) for Initiation of Dupilumab Treatment

    Reason(s) for initiation of dupilumab treatment will be evaluated.

    Time frame: Baseline

  22. Frequency of Adverse Events (AEs) During the Observation Period

    Frequency of AEs will be evaluated during the observation period.

    Time frame: Baseline to up to 24 months

  23. Type of AEs

    Type of AEs will be evaluated during the observation period.

    Time frame: Baseline to up to 24 months

  24. Frequency of Possible Dupilumab-Related Treatment Emergent AEs (TEAEs)

    Frequency of possible dupilumab-related TEAEs will be evaluated during the observational period.

    Time frame: Baseline to up to 24 months

  25. Type of Possible Dupilumab-Related TEAEs

    Type of possible dupilumab-related TEAEs will be evaluated during the observational period.

    Time frame: Baseline to up to 24 months

  26. Occurrence of Product Technical Complaints (PTCs)

    Occurrence of PTCs will be evaluated.

    Time frame: Baseline to up to 6, 12 and 24 months

07

Study locations

18 of 18 sites recruiting
  • Investigational Site Number: DE18
    Auerbach, 08209, Germany
    Recruiting
  • Investigational Site Number: DE21
    Augsburg, 86152, Germany
    Recruiting
  • Investigational Site Number: DE13
    Bad Homburg, 61350, Germany
    Recruiting
  • Investigational Site Number: DE19
    Berlin, 10717, Germany
    Recruiting
  • Investigational Site Number: DE02
    Berlin, 14163, Germany
    Recruiting
  • Investigational Site Number: DE29
    Burgwedel, 30938, Germany
    Recruiting
  • Investigational Site Number: DE01
    Darmstadt, 64283, Germany
    Recruiting
  • Investigational Site Number: DE09
    Erkelenz, 41812, Germany
    Recruiting
  • Investigational Site Number: DE06
    Flensburg, 24937, Germany
    Recruiting
  • Investigational Site Number: DE08
    Fürstenwalde, 15517, Germany
    Recruiting
  • Investigational Site Number: DE03
    Hamburg, 20354, Germany
    Recruiting
  • Investigational Site Number: DE04
    Hamburg, 22459, Germany
    Recruiting
  • Investigational Site Number: DE07
    Hohenstein-Ernstthal, 09337, Germany
    Recruiting
  • Investigational Site Number: DE10
    Itzehoe, 25524, Germany
    Recruiting
  • Investigational Site Number: DE24
    Kaiserslauten, 67655, Germany
    Recruiting
  • Investigational Site Number: DE25
    Lüneburg, 21339, Germany
    Recruiting
  • Investigational Site Number: DE20
    Marburg, 35037, Germany
    Recruiting
  • Investigational Site Number: DE14
    Markkleeberg, 04416, Germany
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2025 (actual). Primary completion is estimated for Jul 2029, 48 months after the start.

Of 120 industry-sponsored observational studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 37. This study's planned 48 months is above that.

Counting every sponsor, half of 589 studies reached it within 26 months; a quarter within 14 and three quarters within 57.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 26, 2025
First posted
Jul 4, 2025
StartActual
Jul 1, 2025
Primary completionEst.
Jul 1, 2029
CompletionEst.
Jul 1, 2029
Last update
Dec 22, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 22, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07052396
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Jul 4, 2025
Start date
Jul 1, 2025
Primary completion
Jul 1, 2029 (estimated)
Completion
Jul 1, 2029 (estimated)
Last update
Dec 22, 2025

Study contacts

Trial Transparency email recommended (Toll free for US & Canada)
Contact
Contact-US@sanofi.com
800-633-1610 ext. option 6
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion